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Overview of thyroid pathophysiology
The thyroid gland forms part of the peripheral endocrine 
system (i.e. those endocrine glands that are situated outside 
the central nervous system). It is characteristically shaped like a 
bowtie (or butterfly), with the central isthmus joining together 
its two lateral lobes. It is situated in the midline, anterior to the 
larynx and trachea, and at the level of the C5 to T1 vertebrae. 
The highly vascular thyroid gland secretes two blood-borne 
thyroid hormones that regulate the rate of the body’s basal 
metabolism (including energy levels and body temperature), 
as well as calcitonin that opposes the net effect of parathyroid 
hormone (PTH) on plasma calcium levels, in the regulation of 
calcium metabolism. The thyroid hormones also play a vital role 
in normal growth and development and are able to augment the 
functions and effects of the sympathetic nervous system.1-5
The two thyroid hormones, which are secreted by the follicular 
cells, are triiodothyronine (T3) and thyroxine (tetraiodothyronine 
or T4), which are both synthesised from tyrosine and iodine. 
Tyrosine is a non-essential amino acid that is synthesised in the 
body, and the iodine is derived from the diet. In the body, the 
negatively charged iodide ions (I-) are actively transported from 
the bloodstream, via the follicular cells, into the colloid of the 
thyroid gland against a steep concentration (electrochemical) 
gradient by the sodium-iodide-symporter.1-5
About 90% of the secreted T4 is converted to T3 in peripheral 
target tissues outside of the thyroid gland. This process of 
activation mainly takes place in the liver and kidneys. T3 is 
significantly more potent than T4. Thyroid hormone secretion 
is regulated via the hypothalamic-pituitary-thyroid gland axis. 
Thyroid-stimulating hormone (TSH) from the anterior pituitary 
gland regulates the secretion of T3 and T4 into the bloodstream. 
In turn, TSH-secretion is regulated by thyroid-releasing hormone 
(TRH) from the hypothalamus. Both T3 and T4 are capable of 
exerting negative or inhibitory feedback upon the release of TRH 
and TSH. Refer to Figure 1.1-5
Figure 2 illustrates the peripheral metabolic pathways of 
thyroxine (T4).
Abnormal secretion of the thyroid hormones
There are two main categories of abnormal thyroid gland 
functioning, namely hypothyroidism (i.e. insufficient thyroid 
hormone secretion) and hyperthyroidism (i.e. an excessive 
secretion of the thyroid hormones).
Hypothyroidism
Hypothyroidism refers to low plasma levels of the thyroid 
hormones due to their inadequate production or secretion 
by the thyroid gland. Inadequate levels of circulating thyroid 
hormone during foetal development and early infancy will result 
in a condition known as cretinism. Three underlying mechanisms 
may result in the hyposecretion of thyroid hormone:
• Inadequate dietary intake of iodine, which is probably the 
most common cause of hypothyroidism worldwide.
• A secondary insufficiency due to deficient levels of TRH and/
or TSH.
• As a result of primary gland failure of the thyroid itself.1,5
Hyperthyroidism
The condition is also referred to as thyrotoxicosis, and is the 
result of excessive, or hypersecretion of thyroid hormone. 
Hyperthyroidism is most commonly caused by an autoimmune 
condition known as Grave’s disease. The other two causative 
mechanisms of hyperthyroidism are:
• Thyroid tumours that secrete excessive amounts of thyroid 
hormone.
• A secondary excess due to abnormally high levels of TRH or 
TSH.1,5
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Laboratory diagnosis of thyroid disorders
Thyroid function tests may be performed, which will typically 
include the levels of TSH, free T4, as well as T3 in the bloodstream. 
In hypothyroidism, the levels of T3 and T4 will be low, with a 
compensatory increase in the level of TSH. The reverse is found 
in thyrotoxicosis, where the TSH-level will be decreased, and the 
free levels of the thyroid hormones conversely increased.1,5
However, the desired TSH-level is a homeostatic concept and 
cannot be adjusted to a fixed range. The homeostatic control 
may shift from feedback, where TSH is inversely related to T4, 
towards tracking where TSH becomes positive. Pituitary TSH 
cannot be accurately interpreted as a reliable image of thyroid 
function, because the TSH-to-T4 correlation is frequently inverted 
or broken by common conditions such as obesity, aging and 
levothyroxine (lT4) treatment. The relationships between thyroid 
hormones, TSH and the engaging elements of the homeostatic 
control system are dynamic, individual and adaptive. This paves 
the way for a paradigm shift in the diagnostic use of the TSH 
measurement.6 
The current paradigm of thyroid diagnosis
The modern paradigm of thyroid function testing was shaped 
by two events, namely the methodological advances in the 
accurate measuring of pituitary TSH and the negative feedback 
mechanism by thyroid hormones on TSH.6 If TSH serum levels 
displayed a more accurate mirror image of associated thyroid 
hormone status than thyroid hormones themselves, this would 
have provided clinicians with an ideal diagnostic tool.6 Since 
the 1980s, TSH measurement gained a primary role in thyroid 
function testing, introducing new definitions of hyper- or 
hypothyroidism, facilitating cost-effective diagnostic screening, 
and providing biochemical treatment targets. Multiple 
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Figure 1. Simplified diagram of the hypothalamic-pituitary-thyroid gland axis
Thyroxine (T4)
Legend:
(+) Positive or stimulatory effect
(-) Negative or inhibitory effect
(+)(-)
(-)
Inactivated via  
deiodination
Activated via  





Reverse T3 (rT3) Triiodothyronine (T3)
5-deiodinase 5’-deiodinase
Figure 2. The peripheral metabolism of thyroxine (adapted from Katzung et al)3
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with clinical outcomes, which led to a highly questionable 
paradigm as a parameter in current guidelines for diagnosis 
and management of thyroid diseases.6 Recent clinical studies 
have revealed fundamental concerns with the interpretation of 
TSH concentrations and documented poor improvement in the 
quality of life of patients receiving treatment for hypothyroidism 
in accordance with the current TSH-based criteria.6 
Shifting the paradigm
The key question to ask is whether a patient’s thyroid hormone 
status is always accurately reflected by the TSH concentration. 
Thyroid hormones, predominantly T4, regulate pituitary TSH 
levels through negative feedback (refer to Figure 1). The primary 
physiological role of TSH is to elevate the hypothyroid to the 
euthyroid state. Without adequate glandular stimulation by 
TSH, as is apparent in secondary hypothyroidism, the primary 
hormone output by the thyroid gland remains subtherapeutic. 
On the other hand, in thyroid health, TSH will raise thyroid 
hormone production to its physiological state, as well as enhance 
the formation of T3 and its conversion from T4.6
A so-called TSH-T3 shunt is incorporated into the homoeostatic 
management of the thyroid-pituitary axis. The shunt enables T3 
stability against glandular T4 variations in output, and its absence 
may result in T3 production inconsistency in athyreotic patients. 
This homeostasis loop still operates within the euthyroid TSH 
range.6
Pathophysiological challenges, other than thyroid disease, may 
also disturb TSH and thyroid hormone equilibria, requiring 
setpoint modification of the hypothalamic-pituitary-thyroid axis. 
Aging, weight gain or loss, and alterations in body composition, 
frequently shift the control mode from negative feedback 
towards tracking T4 rather than opposing it. It is clinically 
important to identify this reversal in TSH-T4 correlation; however, 
it may be misinterpreted as hypothyroidism when the diagnostic 
tests solely rely on TSH measurements.6
Appropriateness versus normality
Range consideration is a different concept from the 
appropriateness of a TSH-level.6 In secondary hypo- or 
hyperthyroidism, TSH-levels may often be inadequate, although 
residing within a normal range, yet abnormally decreased in 
relation to the low T4 level.6 Major statistical issues arise due 
to the high-individuality index of TSH and its relative variation 
with thyroid hormones, because the concept of statistical 
hypothesis testing demands the sample to be representative of 
the population.6 For some individuals, the same TSH value may 
indicate perfectly normal thyroid health, for others declining T4 
concentrations with thyroid failure and a negative association 
between the two hormones, and for others a homoeostatic shift 
towards a positive TSH-T4 correlation.6 Consequently, we cannot 
merely rely on adjusting TSH-levels to within an acceptable 
population range and then expect autoregulation of the thyroid 
hormone to adequately supply tissue with T3.6
There are two primary concerns with this popular assumption 
regarding the ability of the patient’s pituitary gland.6 Firstly, this 
frequently leaves patients dissatisfied, since their quality of life is 
not ultimately restored with lT4 treatment to that seen in healthy 
individuals despite their TSH-levels residing within the reference 
range.6 Secondly, TSH concentrations for patients receiving lT4 
treatment are different to those of untreated persons.6 The 
clinical treatment response to lT4 is diverse and influenced by 
several treatment-related and unrelated factors.6 Because of low-
conversion efficiency in some patients, the TSH equilibrium may 
be shifted below the reference range of a healthy population. 
This poses a significant treatment dilemma to clinicians.6
Toward an individualised treatment strategy
Given the significant changes in thyroid management related 
to lT4 medication, physicians can no longer dismiss patient 
complaints regarding clinical hypothyroid and biochemical 
euthyroid states.6 Advancements in the understanding of 
the diverse aspects of pituitary control suggest replacing the 
current diagnostic paradigm with a more inclusive approach.6 
The proposed paradigm should take into account all three 
thyroid parameters, clinical signs and symptoms, and their 
interrelationships.6 The appropriateness of the particular levels 
relative to each other, the specific condition and the previous 
healthy thyroid state plays a more important part in categorising 
than do conventional reference ranges.6
Unfortunately, fixed-range considerations for TSH-levels do not 
apply to patients receiving lT4 since every patient on lT4 may not 
tolerate or require a suppressed TSH. There is no easy solution, 
but a paradigm shift could be the first step, where treatment 
adequacy is judged on an individual basis together with a 
combination of biochemical and chemical outcomes.6 Table 
I provides a summary of the differences between the current 
thyroid-stimulating hormone (TSH) paradigm and the newly-
proposed relational paradigm.6 
Pharmacology of thyroid drugs
Introduction
Drug therapy used in the management of thyroid conditions 
has been utilised for more than a century. Antithyroid drugs 
are used in the management of hyperthyroidism, whilst drugs 
used to restore normal thyroid hormone concentrations in body 
tissue, are used in the management of hypothyroidism. The latter 
is aimed at providing symptomatic relief, and in newborns to 
prevent neurological deficits (i.e. cretinism), as well as to reverse 
the biochemical abnormalities associated with hypothyroidism.7
Non-pharmacological management
Non-pharmacological measures can also be used in the 
management of hypo- and hyperthyroidism. Hyperthyroidism 
may either be managed by conservative treatment (i.e. 
antithyroid drugs) or by reduction or ablation of the thyroid tissue 
(e.g. radioactive iodine, thyroidectomy).10 In the management 
of hyperthyroidism, the surgical removal of the hypersecreting 
thyroid is an option in patients with clinical symptoms that 
include:8
• Large thyroid (> 80 g)
• Severe ophthalmopathy
• Decreased response to antithyroid drugs
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Following a thyroidectomy, hyperthyroidism may be persistent 
post-surgery in 0.6 % to 17.9 % of patients suffering from Graves’s 
disease, and especially in children. Complications of surgery 
most frequently include hypothyroidism, and less commonly 
hypoparathyroidism and vocal cord abnormalities.7,8
The management of hypothyroidism will depend on the levels 
of thyroid-stimulating hormone (TSH) and the presenting 
symptoms of the patient. Refer to Figure 3 for an overview of the 
management of hypothyroidism.9
Hyperthyroidism
Methimazole, carbimazole, and propylthiouracil (PTU) are 
relatively simple molecules known as thionamides, and contain 
a sulfhydryl group and a thiourea moiety within a heterocyclic 
structure; these drugs are also the mainstay of antithyroid-drug 
therapy.7,10,11 Collectively they are referred to as the antithyroid 
drugs (ATDs). Their main mechanism of action is through 
the blockade of thyroid hormone synthesis by inhibition of 
thyroid peroxidise. This enzyme catalyses iodide oxidation, 
iodination of tyrosine residues into thyroglobulin, and coupling 
of iodotyrosines (monoiodotyrosine (MIT) and diiodotyrosine 
(DIT)) to form the thyronines, tetraiodothyronine or thyroxine 
(T4) and triiodothyronine (T3). An additional effect of PTU is to 
inhibit monodeiodination of thyroxine to triiodothyronine.7,10,11 
They also have immunosuppressive actions, which are useful in 
the management and treatment of Graves’s disease. 
Antithyroid drugs are used in two ways:7
• The primary treatment for hyperthyroidism. 
• Used in preoperative preparation before radiotherapy or 
surgery.
The following conditions may be managed with antithyroid 
drugs: Graves’ disease, toxic adenoma, and toxic multinodular 
goitre. In the case of toxic adenoma and toxic multinodular 
goitre, ATDs are used as a tool to prepare the patient for more 
definitive treatment. Antithyroid drugs are used as the primary 
Table I. A comparison between the current thyroid-stimulating hormone (TSH) paradigm and the newly-proposed relational paradigm6
Current TSH paradigm New relational paradigm
Normality-based approach Homoeostatic equilibria
Univariate normal distribution Multivariate distributions
Population-based range Setpoint, joined TSH–T4 pairs
Low degree of individuality High-individuality index
TSH is reflective of thyroid hormone status TSH is interlocked with T4 and T3
The reference range is fixed across individuals and conditions The setpoint is genetically determined and adjustable to various 
conditions
The parameters are treated as singularities, even when interpreted in 
combination
The parameters are interpreted in relation to each other
Interpreting ranges Reconstructing setpoints
Levels are interpreted as being within the reference range or outside its 
limits
Levels are interpreted as relatively appropriate or inappropriate
A TSH within its reference range in a healthy population indicates 
euthyroidism
The population-based TSH reference range is too wide to reliably define 
euthyroidism in a person
A high TSH indicates overt or subclinical hypothyroidism with rare 
exceptions
A high TSH originates from diverse physiologies
The setting of reference ranges and their interpretation is a simple 
process
The derivation of conjoined homeostatic equilibria constitute an 
intricate process
Subclinical thyroid disease entities are solely based on laboratory 
measurements and do not correspond to treatable clinical entities
The clinical change or challenge is considered primary mounting a 
defensive reaction that may alter the setpoint or transfer function
TSH is frequently interpreted without sufficient consideration of the 
clinical situation
The interpretation of TSH is tied to the clinical presentation
The TSH reference range is universally suitable to judge treatment 
success
A TSH-level is inadequate as a measure of treatment success and lT4 
dose adequacy
The suitable TSH range remains unchanged in lT4-treated patients The suitable TSH range is shifted in lT4-treated patients
Symptomatic hypothyroidism 
• Symptomatic
• TSH levels of > 10 mU/l
• Treatment with levothyroxine most 
probably life-long
Symptomatic hypothyroidism with 
normal TSH levels
• Check for alternative diagnosis
• Treat accordingly
• Test-dosages of levothyroxine 
may be initiated; this may assist in 
diagnosis
Subclinical hypothyroidism
• TSH between 5 and 10 mU/l (free 
serum thyroxine in reference range)
• Routine medicine management is 
controversial
• Levels should be confirmed after 
3–6 months and management  
re-assessed
Figure 3. Overview of the management of hypothyroidism
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treatment option in pregnant patients, as well as in children and 
adolescents.10,11
When prescribed for Graves’ hyperthyroidism, these drugs are 
used to induce a remission, which is defined as having normal 
thyroid hormone levels for one year after drug treatment has 
been stopped.10,11
In the management of hyperthyroidism, and when patients are 
fully compliant with the medicines prescribed, the ATDs may 
be highly effective. The choice of drug to be used is based on a 
decision made between the prescriber and the patient. However, 
methimazole has the advantage of a once-daily dosing regimen 
and serum thyroxine and triiodothyronine levels decrease 
more rapidly in patients treated with this drug. The risk of 
agranulocytosis is also lower with methimazole, and when used 
in moderate dosages may improve compliance and makes this 
drug preferable to propylthiouracil.7,10
Once a patient has been started on treatment of ATD, follow-up 
testing of thyroid function should be undertaken every four to 
six weeks, until the thyroid function is stable or until the patient 
is diagnosed as being euthyroid (i.e. having normal thyroid 
function). Clinically most patients improve considerably after 
four to twelve weeks; drug dosing can be reduced to maintain 
normal thyroid function. Administering the incorrect dosage, 
or not monitoring the dosage, can produce hypothyroidism or 
even goitre. Treatment with ATDs will normally last for 12 to 18 
months.7
Side-effects experienced with ATDs
Antithyroid drugs are associated with side-effects that may 
range from being minor, to being potentially life-threatening or 
even lethal. Methimazole has dose-related side-effects, whereas 
propylthiouracil side-effects seem to be less associated with the 
actual dosage. The milder side-effects are usually self-limiting 
and are observed in less than 5% of cases; these side-effects 
seem to be noticed during the initial phases of treatment when 
the daily dosage administered is higher than usual.10,11
When more severe side-effects are experienced with one agent, 
another thionamide can serve as a substitute; however, cross-
sensitivity has been described in as much as 50% of patient 
cases.7,10,11 Side-effects should be evaluated and if serious the 
drug should be discontinued. Side-effects of the ATDs are listed in 
Table II and have been provided in the form of a checklist, which 
may be utilised by the pharmacist in the practice setting.10,11
β-blockers
β-adrenergic blockers are used in symptomatic management 
of hyperthyroidism due to Graves’ disease or toxic nodules 
awaiting surgery. They are used to reduce the sympathomimetic 
symptoms induced by hyperthyroidism, such as palpitations, 
anxiety and tremors, and should be discontinued once the 
patient becomes euthyroid. All β-blockers may be used in the 
management of hyperthyroidism; atenolol and nadolol may 
improve compliance as they only necessitate a once-daily dosing 
routine. β-blockers should still be used with caution in patients 
with asthma and heart failure as co-morbid conditions.10
Table II. Side-effects of the antithyroid drugs
Body system Side-effect Frequency (and drug 
involved)
Experienced by the 
patient (  or )
Blood Mild leukopenia Relatively frequent
Agranulocytosis Uncommon
Aplastic anaemia Very rare
Thrombocytopaenia Very rare
Pancytopenia Very rare
Skin Skin rash Very common
Urticaria Very common
Itching Very common
Generalised rash Very rare
Alopecia Very rare
Hepatic (liver) Hepatocellular necrosis Rare (PTU)
Cholestasis Very rare (MMI)
Collagen Arthralgia Common
SLE-like syndrome Very rare (PTU > MMI)
Vasculitits Very rare (PTU)
Embryopathy Choanal atresia, esophageal atresia, cardiac defects, aplasia cutis Very rare (MMI)
Situs inversus ± dextrocardia, unilateral kidney a/dysgenesis, cardiac 
outflow tract defect
Very rare (PTU, uncertain)
Miscellaneous Loss of taste Rare (MMI)
Hypothrombinaemia Rare (PTU)
Insulin auto-antibodies Very rare
[MMI = methimazole; PTU = propylthiouracil; SLE = systemic lupus erythematosus]
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Radioactive iodine (RAI)
Recurrent hyperthyroidism and Graves’ disease may be treated 
with radioactive iodine. RAI is used as it causes destruction of 
thyroid tissue with the end-goal of achieving a patient with 
either euthyroid or hypothyroid levels. Sodium iodide 131 (131I) 
is the RAI of choice in the treatment of Graves’ disease and 
toxic autonomous nodules. RAI is a colourless and tasteless 
liquid. Dosing regimens and the contact-time following the 
administration of RAI is not well established; however, low 
dosages may be more convenient for the patient.10,11
Iodides
Iodine is a temporary solution that inhibits the release of thyroid 
hormones for only a few days or weeks (one to two weeks), 
and for this reason its usefulness is limited to the preparation 
of patients with Graves’ disease for surgery, as well as to treat 
patients suffering from a thyrotoxic crisis. The inhibitory effect is 
achieved via the blocking of hormone release, by interfering with 
hormone biosynthesis through competing with intrathyroidal 
iodide use. This decreases the size and vascularity of the thyroid 
gland. Preparations are available as either a saturated potassium 
iodide solution (SSKI) or as a Lugol’s solution.10,11
Hypothyroidism
When hypothyroidism is left untreated it can result in cardiac 
failure, psychosis, and coma.12 Thyroxine-replacement therapy is 
highly effective and has been used in its rudimentary form since 




• Thyroid-stimulating hormone (TSH) suppression therapy in 
patients suffering from thyroid cancer
Levothyroxine (T4; l-thyroxine) is a synthetic thyroid hormone and 
remains the drug of choice for thyroid-replacement therapy as it 
is chemically stable, not expensive, and with uniform potency.14 
Dosages of levothyroxine (lT4) can be related to bodyweight 
(dosed at 1.8 µg per kg in adults, 0.5 µg per kg in older adults) and 
is dosed at higher levels in infants and young children.14 When 
therapy is initiated it should be at the lower end of the calculated 
dose; i.e. for a 70 kg adult, 125 µg per day.15 To initiate therapy 
at 25–50 µg per day and titrating upwards is unnecessary and 
prolongs the desired response to treatment.14,15 Dosages should 
be titrated using serum thyrotropin concentrations and should 
be undertaken four to six weeks after a new thyroxine dosage 
has been prescribed. Thereafter, this should be done annually, or 
whenever a patient presents with persistent symptoms of either 
hypo- or hyperthyroidism.14
The target level of treatment is determined by the following:15
• The patient expressing a sense of well-being, with signs and 
symptoms decreasing in frequency and severity
• TSH-levels at the lower end of the reference range (0.4 to 
2.5 mU/l)
It is important to avoid a fully-suppressed TSH (< 0.1 mU/l); each 
patient should be assessed using TSH-levels and symptoms, 
and dosed individually.15 Patient counselling when initiating the 
therapy should include the advice as listed in Table III.
Side-effects experienced with levothyroxine therapy
Side-effects experienced with thyroid-replacement therapy are 
related to excessive thyroid hormone action and may include the 
following:6,11,15
• Symptomatic thyrotoxicosis





Patients who were previously diagnosed with underlying 
ischaemic heart disease may exacerbate myocardial ischaemia 
once euthyroidism has been established.11,15 Synthetic products 
very rarely produce allergic or idiosyncratic reactions, as were 
previously experienced with the natural or animal-derived 
products.5
Hyperthyroidism may lead to a decrease in bone density due to 
hyper-remodelling of the cortical and trabecular bone, which 
could result in an increased likelihood of bone fractures.5 Acute 
sympathomimetic symptoms and hair loss have also been 
experienced after thyroxine treatment has been initiated.12
Table III. Patient advice when initiating levothyroxine therapy15
Patient advice Experienced by the 
patient (  or )
It may take a week or more for you to start feeling better. Levothyroxine has a half-life of seven days.
If you miss one dose, the effect might not be noticeable (due to the long half-life); take as soon as you remember.
Other symptoms (e.g. muscle stiffness/weakness and mental effects may take several months to resolve once the chemical 
imbalance has been corrected).
Levothyroxine should be taken on an empty stomach, it will maximise absorption.
Treatment will be life-long, and dose adjustments will only be made according to hormone (thyroid) levels. Hormone levels 
should be taken once a year.
The following drugs should be avoided or taken with caution when taking levothyroxine therapy:
Drugs that will prevent absorption of levothyroxine (e.g. calcium salts, ferrous sulphate, aluminium hydroxide, cholestyramine).
Drugs that increase the clearance of levothyroxine, in other words drugs that will cause a decrease in levothyroxine levels (e.g. 
phenytoin, carbamazepine, phenobarbitone and rifampicin).
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Conclusion
The thyroid gland plays a vital role in the maintenance of a 
normal basal metabolism in the human body. Abnormalities 
in thyroid hormone levels could, therefore, have far-reaching 
effects on various body systems, organs and tissues. Such 
abnormalities typically fall into one of two categories, namely 
hypo- or hyperthyroidism, and require effective treatment 
to either replace the deficient levels of thyroxine in the 
bloodstream, or to antagonise the excessive levels of circulating 
thyroid hormone. Patients who are using such therapies in the 
long-term will require additional monitoring and support from 
the multidisciplinary team, including the pharmacist.
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